Back to VRTX Stock Lookup

Vertex Pharma (VRTX) – Company Press Releases

Apr 27, 2016 04:01 PM Vertex Reports First Quarter 2016 Financial Results
Apr 18, 2016 11:30 AM Enterome In-licenses Novel Compounds From Vertex Pharmaceuticals to Treat Microbiome-related Inflammatory Bowel Diseases
Apr 15, 2016 08:30 AM Vertex to Announce First Quarter 2016 Financial Results on April 27
Mar 30, 2016 09:00 AM MC10, Inc. Appoints Eric K. Brandt to its Board of Directors
Mar 10, 2016 04:01 PM Vertex to Present at the Barclays Healthcare Conference on March 15
Mar 8, 2016 03:05 PM Vertex Receives Australian Approval for ORKAMBI® (lumacaftor/ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del
Feb 24, 2016 09:05 AM Vertex Awards $1 Million in Grants to 18 Non-profit Organizations to Advance Initiatives for People Living with Cystic Fibrosis
Feb 9, 2016 08:00 AM Vertex to Present at Upcoming Investor Conferences
Feb 5, 2016 08:00 AM Vertex Receives Complete Response Letter from U.S. FDA for Use of KALYDECO® (ivacaftor) in People with Cystic Fibrosis Ages 2 and Older with One of 23 Residual Function Mutations
Jan 27, 2016 04:01 PM Vertex Reports Full-Year and Fourth Quarter 2015 Financial Results
Jan 26, 2016 05:20 PM Health Canada Approves PrORKAMBI® (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation
Jan 10, 2016 04:00 PM Vertex Outlines 2016 Business Priorities to Support the Discovery and Development of New Transformative Medicines for the Treatment of Cystic Fibrosis and Other Serious Diseases
Jan 5, 2016 09:00 AM Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth Quarter and Full Year 2015 Financial Results
Nov 23, 2015 04:01 PM Vertex to Present at the Piper Jaffray Healthcare Conference on December 1
Nov 23, 2015 08:30 AM Vertex Appoints Michael J. Parini as Executive Vice President and Chief Legal Officer
Nov 20, 2015 03:30 AM Vertex Receives EU Approval for ORKAMBI® (lumacaftor/ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutatio
Nov 18, 2015 03:30 AM Vertex Receives Two EU Approvals for KALYDECO® (ivacaftor) for People with Cystic Fibrosis
Nov 5, 2015 07:00 AM Pronutria Biosciences Announces Jennifer Che, J.D., as Vice President, Intellectual Property Counsel
Nov 4, 2015 04:01 PM Vertex to Present at the Credit Suisse Healthcare Conference on November 10
Nov 2, 2015 05:00 AM IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims against Vertex Pharmaceuticals Incorporated and Encourages Investors to Contact the Firm
Oct 28, 2015 04:01 PM Vertex Reports Third Quarter 2015 Financial Results
Oct 26, 2015 08:00 AM Vertex and CRISPR Therapeutics Establish Collaboration to Use CRISPR-Cas9 Gene Editing Technology to Discover and Develop New Treatments for Genetic Diseases
Oct 9, 2015 09:00 AM Vertex to Announce Third Quarter 2015 Financial Results on October 28
Oct 8, 2015 09:00 AM Vertex Announces Significant Progress in Its Development Efforts to Treat the Cause of Cystic Fibrosis in the Vast Majority of People with the Disease
Oct 7, 2015 04:53 PM Supplemental New Drug Application for Use of KALYDECO® (ivacaftor) in People with Cystic Fibrosis Ages 2 and Older who have One of 23 Residual Function Mutations Accepted for Priority Review by U.S.
Sep 25, 2015 07:17 AM Vertex Receives CHMP Positive Opinions for ORKAMBI™ (lumacaftor/ivacaftor) and KALYDECO® (ivacaftor) in the European Union
Sep 8, 2015 04:01 PM Vertex to Present at the Morgan Stanley Healthcare Conference on September 16
Aug 19, 2015 02:35 PM Vertex Awards Two Boston Public High School Students the Vertex Science Leaders Scholarship to the University of Massachusetts
Jul 29, 2015 04:01 PM Vertex Reports Second Quarter 2015 Financial Results
Jul 14, 2015 09:00 AM Vertex to Announce Second Quarter 2015 Financial Results on July 29
Jul 2, 2015 01:46 PM FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation
Jul 2, 2015 01:46 PM ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutat
Jun 18, 2015 04:01 PM Sangeeta N. Bhatia, M.D., Ph.D., Joins Vertex Board of Directors
Jun 11, 2015 09:00 AM Vertex Announces Data Presentations at European Cystic Fibrosis Society (ECFS) Conference
Jun 4, 2015 04:01 PM Vertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC) Inhibitors in Cystic Fibrosis and Other Pulmonary Diseases
Jun 4, 2015 04:01 PM Vertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC) Inhibitors in Cystic Fibrosis and Other Pulmonary Diseases
Jun 4, 2015 04:01 PM Vertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC) Inhibitors in Cystic Fibrosis and Other Pulmonary Diseases
Jun 3, 2015 04:01 PM Vertex to Present at the Goldman Sachs Healthcare Conference on June 11
May 17, 2015 01:32 PM New England Journal of Medicine Publishes Data from Two Phase 3 Studies of ORKAMBITM (lumacaftor/ivacaftor) in People with Cystic Fibrosis who have Two Copies of the F508del Mutation
May 13, 2015 04:01 PM Vertex to Present at the UBS Healthcare Conference on May 19
May 12, 2015 04:15 PM Food and Drug Administration Advisory Panel Voted 12 to 1 to Recommend Approval of ORKAMBI™ (lumacaftor/ivacaftor) to Treat People with Cystic Fibrosis Ages 12 and Older Who Have Two Copies of the F
Apr 29, 2015 04:01 PM Vertex Reports First Quarter 2015 Financial Results
Apr 9, 2015 04:01 PM Vertex to Announce First Quarter 2015 Financial Results on April 29
Mar 23, 2015 07:45 AM Vertex Announces Data from 12-Week Phase 2 Safety Study of VX-661 in Combination with Ivacaftor in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation
Mar 18, 2015 07:46 AM Vertex Receives U.S. Food and Drug Administration Approval of KALYDECO® (ivacaftor) for Children with Cystic Fibrosis Ages 2 to 5 who have Specific Mutations in the CFTR Gene

Back to VRTX Stock Lookup